Core Insights - Heng Rui Medicine has received clinical trial approval for two drugs, SHR-2173 and HRS-9821, from the National Medical Products Administration, indicating progress in its innovative drug development pipeline [1][2] Group 1: Drug Development - SHR-2173 is a self-developed biological product targeting abnormally activated immune cells, aimed at treating primary membranous nephropathy, with a total R&D investment of approximately 64.07 million yuan [1] - HRS-9821 is a small molecule PDE3/PDE4 inhibitor intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with a total R&D investment of about 38.43 million yuan [1] - The global market for similar products includes Ensifentrine, which is expected to generate sales of approximately 42 million dollars in 2024 [1] Group 2: Company Strategy and Market Position - Heng Rui Medicine has been focusing on innovative R&D, having obtained approvals for 23 first-class innovative drugs and 4 second-class new drugs in China, with over 90 self-innovated products currently in clinical development [2] - The company has expanded its research into various therapeutic areas, including metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [2] - Heng Rui Medicine's recent listing on the Hong Kong Stock Exchange marks a significant step in its internationalization strategy, enhancing its global brand influence and attracting foreign investment [3]

Core Viewpoint - The announcement indicates that the subsidiary Aitemei (Suzhou) Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of Tiotropium Bromide Inhalation Powder for the treatment of Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1 - Aitemei has been granted a Clinical Trial Approval Notice for Tiotropium Bromide Inhalation Powder, which is intended for use in COPD [1] - The projected domestic sales for Tiotropium Bromide Inhalation Powder are 555 million yuan in 2022, 522 million yuan in 2023, and 493 million yuan in 2024 [1] - The drug must undergo clinical trials and receive further approval before it can be manufactured and marketed, indicating that there will be no significant short-term impact on the company's operations [1]